Sanofi delivered 2015 business EPS up 8.5%
Sales growth in Pharmaceuticals, Vaccines and Animal Health in 2015
The aggregate Group sales went up 2.2% (+9.7% at 2015 exchange rates) to €37,057 million with Genzyme continuing to be a key driver with sales up 29.5% with strong momentum in multiple sclerosis. Sales of vaccines were up 7.3% benefiting from double-digit growth in Emerging Markets. Diabetes sales decreased 6.8% in line with October guidance, reflecting lower U.S. sales of Lantus®. The animal health business demonstrated strong performance with sales up 10.8% driven by NexGard®. Strong grow in China by 19.5% drives emerging market sales increased by 7.8%.
Solid financial results in 2015:
- Business EPS was €5.64, up 8.5% on a reported basis and stable at CER
- Free Cash Flow up 12.2% to €8,132 million resulting in net debt of €7,254 million
- Board proposes dividend of €2.93, the 22nd consecutive year of dividend growth
Sanofi expects 2016 Business EPS to be broadly stable at CER, barring unforeseen major adverse events
Sanofi Chief Executive Officer, Olivier Brandicourt, commented: "In 2015, Sanofi made meaningful progress with key launches, multiple business development activities and our efforts to simplify the organization. Entering into exclusive negotiations on a business swap with Boehringer Ingelheim would bring us leadership in CHC. This is a key first step in reshaping our portfolio. In 2016, we continue to allocate resources to our promising late-stage pipeline and the introduction of innovative medicines which will position us for accelerated future growth".
Other news from the department business & finance
